Cambridge, mass. ,, June 23, 2025 / Prnewswire / – Xtalpi, a world leader in the discovery of drugs and materials fueled by AI and robotics, announced today that it had signed a letter of intent (law) with Dovetree LLC, founded by Harvard University Renowned biopharma teacher and entrepreneur Gregory Verdine. The parties intend to execute a final agreement shortly. Under collaboration, Xtalpi will take advantage of its end-to-end platform, AI and robotics to discover and develop small molecules and antibody drugs for multiple targets selected on oncology, autoimmune disorders and neurological diseases.
In accordance with the law, Xtalpi will receive an initial payment of $ 51 million within 10 days of the execution of the final agreement and a $ 49 million within 180 days. Subject to the conditions of the final agreement, Xtalpi is also eligible to receive potential development and payments of commercial milestones exceeding $ 10 billionas well as fees with a figure on a figure on annual sales of net products. DOVETREE will obtain exclusive development and marketing rights on the resulting therapies.
Teacher Gregory VerdineChemistry professor Erving at Harvard Universityis a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed Harvard Faculty at 29 years old, he has become the youngest full professor of the Department of Chemistry for almost five decades at 35. He elucidated the molecular mechanism of epigenetic DNA methylation And revealed the paths by which certain genotoxic forms of DNA damage are identified and eradicated. It is a leading figure in the field of new therapeutic methods, and has developed a new class of therapies called peptides stapled, allowing the development of targets against targets long considered as without problem.
As an entrepreneurial leader, Professor Verdine has founded or co-founded on ten biotechnology companies, including five listed entities on the stock market: starta pharmaceuticals (NASDAQ: Enta), Tokai Pharmaceuticals (Nasdaq: Tkai) and Wave Life Sciences (NASDAQ: WVE), among others. A company has been acquired by a large pharmaceutical company, while others continue to develop disruptive drugs with a particular accent on oncology. Three therapies he directed – Fromidepsine (ISTODAX®), Paritaprevir (a component of Viekira Pak®) and Glecaprevir (a component of Mavyret®) – have received approval from the FDA.
Professor Verdine is currently a party capital partner at Andreessen Horowitz (A16Z), a role he previously held at Apple Tree Partners, Third Rock Ventures and Wuxi Healthcare Ventures. He was also a special advisor to Texas Pacific Group. Its advisory commitments include the main research institutions such as the US National Cancer Institute and Harvard medical school.
“By integrating Xtalpi cutting -edge AI capabilities with decades of expertise in drug development, we have a unique opportunity to provide transformative therapies to patients around the world,” said Professor Verdine.
About Xtalpi
Xtalpi Holdings Limited (Xtalpi, 2228.hk) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (WITH). It is an innovative R&D platform powered by quantum physics, artificial intelligence and robotics. By integrating the calculations of the first principles, AI algorithms, high performance cloud computing and standardized automation systems, XTALPI provides digital and intelligent R&D solutions for companies in the pharmaceutical sectors, materials, agricultural technology, energy, new chemicals and cosmetic industries.
Show original content to download the multimedia:https://www.prnewswire.com/apac/News-releases/xtalpi-annouces-strategic-c collaboration-with-harvard-pofessor-gregory-verdines-covetree-lc-to-dvance-novel-3024822222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222222
Source Xtalpi Inc.
